Genentech cuts eye docs out of Avastin

Off-label scrips usually add to a drug maker's coffers. But when eye doctors prescribe the cancer remedy Avastin for macular degeneration, they're cannibalizing Genentech's eye drug Lucentis. So Genentech has moved to block Avastin sales to the outlets eye docs use most often--compounding pharmacies that split up large vials of Avastin into many small doses for ophthalmic use.

The FDA has said it's worried that pharmacists might introduce germs into Avastin when repackaging it. But something tells us that's not the only reason behind the change. Avastin, you see, costs some $40 for eye use--and it's considered nearly as effective as Lucentis, which costs $2,000. If eye doctors didn't use Avastin, Genentech probably would see its Lucentis sales double to $800 million or $900 million. That's not chump change.

- check out the article from the San Francisco Chronicle

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.